Spotlight On... UCB wins FDA nod for another epilepsy drug; Onconova sheds staff; and more...

Belgian drugmaker UCB picked up FDA approval for a treatment designed to treat seizures in patients with epilepsy. The drug, brivaracetam, beat out a placebo in cutting back partial-onset seizure frequency and improving response rates in a Phase III trial. It's now approved as an add-on treatment to existing epilepsy therapies, the FDA said. UCB plans to launch it under the brand name Briviact, marking the third approved treatment in the company's banner epilepsy franchise. More

@FierceBiotech: Novartis' blood cancer drug bags a 'breakthrough' tag on the way to FDA filing. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Adimab issues a challenge: Use new tech to build a rapid-response R&D platform for infectious diseases. News | Follow @JohnCFierce

@DamianFierce: Voice actors share how they deliver drug ad warnings without sounding, well, scary. More | Follow @DamianFierce

> Pennsylvania biotech Onconova Therapeutics ($ONTX) is laying off 6 staff members, 17% of its payroll, to conserve cash as it works through Phase III development of a once-failed cancer drug. News

> China's nascent biotech scene is on the rise thanks to a boom in funding, the Financial Times reports. Story

> Federal prosecutors said they're having trouble convincing potential witnesses to testify against former biopharma CEO Martin Shkreli. Item

Medical Device News

@FierceMedDev: FDA warns two diagnostics players for marketing unapproved tests. More | Follow @FierceMedDev

@EmilyWFierce: AstraZeneca bags EU approval for gout drug Zurampic as it eyes $500M in sales. Article | Follow @EmilyWFierce

> Google's life science arm relocating to South San Francisco. More

> Materialise partners with Mathys to offer 3-D printed, personalized shoulder surgery guides. Story

Pharma News

@FiercePharma: NEJM study finds Actos holds off repeat strokes, heart attacks in insulin-resistant patients. Story | Follow @FiercePharma

@EricPFierce: New York gives $200M for Athenix to build Buffalo plant. Company pledges 900 jobs over 10 years. Story | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday: U.K. cost gatekeepers say 'show me' to Alexion's new rare disease med Kanuma. Item | Follow @CarlyHFierce

> FDA approves UCB drug for treating epileptic seizures. Story

> Teva offers up concessions for quick EU review of Allergan deal. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.